Lost 1.1 billion! 1.1 new drugs can turn this pharmaceutical company around?

Recently, tailing pharmaceutical announced that the new indication "myelodysplastic syndrome (MDS)" of the company's national 1.1 new drug, xiticol (uropolypeptide injection), was included in the "major new drug creation" project of the Ministry of science and technology and the health and Family Planning Commission, and was funded by the central Ministry of finance It can be used in the treatment of non-small cell lung cancer and breast cancer Some experts have predicted that it will be the next big potential drug with a sales volume of more than 1 billion   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; font-size: 16px; line-height: 25.6px; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); Box sizing: border box! Im portant; word wrap: break word! Im portant; "> cedik: a national class 1.1 new drug, the world's first general name of cedik is uropolypeptide injection, which was originally developed by Hefei Yongsheng Pharmaceutical Co., Ltd and approved by CFDA in 2004 for the treatment of malignant lung and breast tumors It is also an exclusive category 1 new drug in China In May 2013, tailing pharmaceutical announced that it had acquired the intellectual property rights (including patents, know-how and trademarks) of xidike from Hefei Yongsheng pharmaceutical, and the total price of the transfer agreement was 30.5 million yuan (about 38.5 million Hong Kong dollars at that time) Uridine injection is a new non cytotoxic anti-tumor preparation, which is made up of a group of natural active ingredients extracted and purified from fresh urine After more than 30 years of research, Dr Liao Minghui, a Chinese American scientist from Texas Cancer Research Center, has found a breakthrough in the anti-cancer mechanism of uric acid polypeptide, which can selectively inhibit the activity of abnormal methyltransferase complex in tumor cells and induce the differentiation and apoptosis of cancer cells In January 2014, tailing pharmaceutical obtained CFDA approval for phase II clinical application of new indications of "myelodysplastic syndrome (MDS)" MDS is a kind of malignant hematopathy, about one third of patients will develop into leukemia At present, there is no corresponding drug of the same type in the global market Recently, the good news came from tailing medicine again The MDS project of new indications of cedik was included in the "major new drug creation" project of the Ministry of science and technology and the health and Family Planning Commission, and was funded by the central Ministry of finance   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; font-size: 16px; line-height: 25.6px; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); Box sizing: border box! Im assistant; word wrap: break word! Im assistant; "> once lost 1.1 billion yuan, tailing pharmaceutical successfully transformed itself On April 20, 2011, tailing pharmaceutical was listed on the main board of Hong Kong stock exchange According to the data, in 2011, the turnover of the company exceeded 2.758 billion yuan, gross profit was 891 million yuan, operating profit was close to 366 million yuan, and equity shareholders of the company accounted for 234 million yuan of profit In terms of four indicators, tailing pharmaceutical at the initial stage of listing has outstanding performance In 2012, under the influence of "anti drug restriction order", there was pressure on the performance of fudaxin (ceftazidime for injection produced by GSK), the product that contributed the most revenue to the enterprise, with the revenue reduced by 50.7% compared with 2011 Another major product, tumor drug libaoduo (doxorubicin hydrochloride liposome injection), also suffered a major setback, mainly because the manufacturer Shanghai Fudan Zhangjiang biopharmaceutical Co., Ltd., in order to meet the new GMP standard, had a tight production capacity when updating the equipment, with the revenue reduced by 30.5% compared with the previous year In addition, the government's strict control over imported vaccines has increased the difficulty for enterprises to collect arrears, which has led to problems such as shrinking profits and unsalable inventory Under the influence of various pressures, the operating profit and loss of tailing pharmaceutical reached 1.1 billion yuan in that year In the face of huge losses, thaling pharmaceutical has made great determination to restructure, quit the vaccine business with low profit margin, reduce the vaccine promotion and sales team, and terminate several dermatology products and over-the-counter medicine businesses In 2013, the operating profit and loss of tailing pharmaceutical was reduced to RMB 578 million, and the profit and loss attributable to equity shareholders of the company was reduced to RMB 673 million In 2014, after two years of business restructuring, tailing pharmaceutical transformed from a major third-party product distributor to a comprehensive pharmaceutical company with core own products and R & D capabilities Tumor and central nervous system are the core professional treatment fields The enterprise has two main tumor products: ribaud and xitico In order to meet the future needs of xitico, tailing pharmaceutical has invested more than 100 million yuan to build a new factory in Taizhou The main products of central nervous system are Shusi (quetiapine fumarate tablets) produced by Suzhou first pharmaceutical Co., Ltd., a wholly-owned subsidiary In 2015, tailing pharmaceutical's business scope covers four major treatment fields: tumor, central nervous system, liver disease and respiratory system In order to focus resources on the development of the company's tumor and central nervous system drugs, the new Taizhou factory specially built for xidique was completed in March 2015 In July of the same year, thaling pharmaceutical decided to stop promoting fudaxin made by GSK In August of the same year, tailing pharmaceutical purchased Hunan Kexing Jimeng Pharmaceutical Co., Ltd with a total price of 95 million yuan, and assisted the company to repay about 13.54 million yuan to its creditors So far, tailing pharmaceutical has included Songzhi pill, the only Chinese patent medicine approved by CFDA for the treatment of hepatitis C In addition, libaoduo successfully won the bid to become the only doxorubicin hydrochloride liposome injection in serious illness medical insurance products in Zhejiang Province, which lasted for two years from January 1, 2015 to January 1, 2017, and also became a major driving force for the company's performance improvement Respiratory system drugs are mainly zhuo'ao (ambroxol hydrochloride for injection) produced by Suzhou first pharmaceutical Co., Ltd In 2016, tailing's business scope covers cancer and blood, orthopedics, central nervous system, liver disease and other treatment fields In March 2017, the new plant of xidiktaizhou obtained GMP certificate, and the production line was officially put into production In July 2016, thaling Pharma purchased miguir injection from Novartis, with a total purchase price of $145 million, strategically entering the field of orthopedic treatment After the successful transformation, the performance of tailing pharmaceutical has greatly improved In 2016, the turnover exceeded 915 million yuan, the gross profit was close to 494 million yuan, the operating profit was close to 186 million yuan, and the equity shareholders of the company should account for 116 million yuan   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; font-size: 16px; line-height: 25.6px; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); Box sizing: border box! Im portant; word wrap: break word! Im portant; "> the second largest shareholder increased its holdings strongly, and the potential of tailing pharmaceutical was optimistic On April 27, 2016, tailing pharmaceutical issued a notice, saying that it had signed a strategic cooperation framework agreement with ANGLI, Jiaotong University Two of the key contents are related to the key products of tailing pharmaceutical, including: ANGLI will help tailing pharmaceutical, open up the hospital channels under ANGLI, assist tailing pharmaceutical to expand the sales and market share of libaoduo, Songzhi pill, xidike and other products; both sides agree to cooperate in the development, promotion and marketing of functional health food related to Songzhi pill and xidike ANGLI of Jiaotong University is the first listed company in the health care industry in China It entered A-share market in 2001 and is committed to the integration of investment in the health care industry, and plans to invest strategically in the field of innovative drugs According to the announcement, ANGLI is the second largest shareholder of tailing Pharmaceutical Co., Ltd and intends to further increase its shareholding in the market, hoping that both sides can carry out comprehensive strategic cooperation in the major health industry, give full play to their respective advantages and achieve win-win results As of the end of 2016, ANGLI held 11.28% of shares in tailing pharmaceutical none="shifuMouseDown('shifu_t_002')" style="margin: 1em auto; padding: 0.5em 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; font-size: 16px; line-height: 25.6px; border: none; text-align: center; width: 670px; box-sizing: border-box !im portant; Word wrap: break word! Im assistant; "> it only took two years for tailing pharmaceutical to successfully transform from a distributor to an innovative pharmaceutical enterprise, and the decision of the manager can indeed stop the loss of the enterprise quickly After the transformation, tailing pharmaceutical concentrated its efforts on product sales, acquisition and product line expansion, and non-stop research and development of new products, so that the performance of the enterprise returned to the right track in a short period of time, and continued to rise After years of training, the original low-cost acquisition of xidike has not only added indications, but also obtained the funding from the central Ministry of finance, which is expected to become the next billion varieties Next, what miracles will teling medicine bring? We will see Source: annual report and announcement of listed companies